What is Eureka Bio?
Headquartered in Shenzhen, China, Eureka Bio operates as a critical upstream core supplier within the cell and gene therapy (CGT) ecosystem. By focusing on the development of pivotal biotechnology and autonomous equipment, the company addresses the complex manufacturing challenges inherent in advanced therapeutic production. Its market position is defined by its ability to provide the essential tools required for the industrialization of CGT, effectively bridging the gap between laboratory-scale research and large-scale clinical manufacturing. As the demand for personalized medicine grows, Eureka Bio's infrastructure-centric approach provides a scalable foundation for global pharmaceutical partners.
How much funding has Eureka Bio raised?
Eureka Bio has raised a total of $40M across 1 funding round:
Series B
$40M
Series B (2024): $40M with participation from Yuexiu Financial Holdings Group
Key Investors in Eureka Bio
Yuexiu Financial Holdings Group
Guangzhou Yuexiu Industrial Investment Fund is a financial corporation specializing in market-competitive equity investment and real estate mezzanine businesses, with a focus on scaling industrial growth.
What's next for Eureka Bio?
Looking ahead, the infusion of capital is expected to drive the expansion of Eureka Bio's manufacturing capabilities and the refinement of its proprietary autonomous equipment. The company is well-positioned to leverage this major strategic investment to deepen its penetration into international markets, particularly as regulatory frameworks for gene therapy continue to mature. By prioritizing the optimization of upstream processes, Eureka Bio aims to reduce the cost and complexity of therapeutic delivery, ultimately enhancing the accessibility of life-saving treatments. Future growth will likely focus on strategic partnerships and the continuous iteration of its technological stack to maintain its competitive edge in the high-stakes biotechnology landscape.
See full Eureka Bio company page
